In the attached pdf-document you will find more detailed information on the distribution of the dividend and the resolution on the appropriation of the balance sheet profit for the year 2021.
Increase in turnover of the operating companies to 37.25 million euros mainly due to new business
EBIT almost twelve times higher at 1.9 million euros
Increased sales forecast from June 2022 confirmed for the 2022 financial year
In the 1st half of 2022, B.M.P. Pharma Trading AG was able to increase the turnover of the operating companies from 18.94 million euros to 37.25 million euros in a very volatile environment. This growth of 96.6% shows that despite the challenging and dynamically changing market, the company is well positioned to continue to grow, to be successful and to remain so in the future.
In the European market, BMP was able to continue the very pleasing development of the previous year in the first six months of 2022 and significantly increase sales revenues. The order backlog of the operating companies remains at a very high level. In addition, the new “Feed & Function by BMP” division is being developed at full speed in order to meet the sustainable growth trend in the feed supplements sector. In Latin America, BMP succeeded above all in stabilising the existing pharmaceutical business, continuing to reliably supply existing customers and winning new customers. Demand in our core markets, food supplements and APIs, remains intact.
The growth of the BMP Group resulted from considerable increases in earnings in all business areas as well as higher sales prices and is also reflected in the earnings development in the first half of 2022. Despite extreme increases in raw material, energy and transport costs, the company was able to increase earnings before interest and taxes (EBIT) almost twelvefold to €1.9 million, thus strengthening its profitability.
Henning A. Nau, CEO of B.M.P. Pharma Trading AG: “The environment, with the weak euro, uncertainties with the war in Ukraine, product shortages as well as inflationary tendencies, did not make it easy for us in the 1st half of 2022. It is all the more pleasing that we can rely on our strengths at all times: our excellent, close relationships with our suppliers and customers, our global logistics expertise and our product know-how. It is precisely this best possible independence from volatile factors that has enabled us to maintain our high service quality and delivery reliability.
In addition, I don’t want to forget to thank my team, which has shown that it can rise above itself and stick together in difficult times. This commitment makes me proud and shows that we are a reliable partner for you even in times of crisis.”
For the 2022 financial year, the Executive Board confirms the heightened expectation in June of a “strong to particularly strong” increase in turnover for the operating company B.M.P. Bulk Medicines & Pharmaceuticals GmbH to over €50.0 million. The other forecasts published in the 2021 annual financial statements also remain valid.
The detailed half-year financial report 2022 is available for download on the website www.bmp.ag